Completed PHASE1 INTERVENTIONAL 1-arm NCT00471133

Safety and Immunogenicity of a Melanoma DNA Vaccine Delivered by Electroporation

A Phase Ia/Ib Study of the Safety and Immunogenicity of a Xenogeneic Tyrosinase DNA Vaccine Melanoma

Sponsor: Ichor Medical Systems Incorporated

Conditions Intraocular Melanoma Melanoma (Skin)

Interventions TriGrid Delivery System for Intramuscular Electroporation Xenogeneic Tyrosinase DNA Vaccine

Updated 6 times since 2017 Last updated: Jun 3, 2011 Started: Apr 30, 2007 Primary completion: May 31, 2010 Completion: May 31, 2010

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE1 clinical study on Intraocular Melanoma and Melanoma (Skin), this trial is completed. The trial is conducted by Ichor Medical Systems Incorporated and has accumulated 6 data snapshots since 2007. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1
Jun 2018 — Jan 2021 [monthly]

Completed PHASE1
Feb 2017 — Jun 2018 [monthly]

Completed PHASE1

▶ Show 1 earlier version

Jan 2017 — Feb 2017 [monthly]

Completed PHASE1

First recorded

Apr 2007

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Ichor Medical Systems Incorporated
Memorial Sloan Kettering Cancer Center

Data source: Ichor Medical Systems Incorporated

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• New York, United States